Figure 5.
Synthetic lethality between RB1 and aryl hydrocarbon receptor (AhR) in bladder cancer.(A) Short-term cell viability assay in T24 and 5637 cells treated with increasing concentrations of BAY-2416964. Cell viability was measured 24 h after drug treatment. Data are presented as mean ± s.d. (n = 3). *P < .05; **P < .01; ***P < .001 . (B) Short-term cell viability assay in p53 wild-type (WT) and p53 null RPE1-hTERT cells treated with increasing concentrations of BAY-2416964. Cell viability was measured 24 h after drug treatment. Data are presented as mean ± s.d. (n = 3). (C) Short-term cell viability assay in T24 cells expressing either scramble shRNA or shRNA targeting Rb1 and treated with increasing concentrations of BAY-2416964. Cell viability was measured 72 h after drug treatment. Data are presented as mean ± s.d. (n = 3). (D) Quantitative RT-qPCR analysis of Rb1 knockdown in indicated T24 cell lines. ****P < .0001.

Synthetic lethality between RB1 and aryl hydrocarbon receptor (AhR) in bladder cancer.(A) Short-term cell viability assay in T24 and 5637 cells treated with increasing concentrations of BAY-2416964. Cell viability was measured 24 h after drug treatment. Data are presented as mean ± s.d. (n = 3). *P < .05; **P < .01; ***P < .001 . (B) Short-term cell viability assay in p53 wild-type (WT) and p53 null RPE1-hTERT cells treated with increasing concentrations of BAY-2416964. Cell viability was measured 24 h after drug treatment. Data are presented as mean ± s.d. (n = 3). (C) Short-term cell viability assay in T24 cells expressing either scramble shRNA or shRNA targeting Rb1 and treated with increasing concentrations of BAY-2416964. Cell viability was measured 72 h after drug treatment. Data are presented as mean ± s.d. (n = 3). (D) Quantitative RT-qPCR analysis of Rb1 knockdown in indicated T24 cell lines. ****P < .0001.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close